Internal medicine journal · 2026
Feasibility and outcomes of kidney transplantation in patients with end-stage kidney disease after haemopoietic stem cell transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Bioh, Choi Seunghyeok, Lee Hanbi, Yoon Hye-Eun, Nam Hohyung, Park Silvia, Chung Byung Ha
Аннотация
BACKGROUND: Advances in haemopoietic stem cell transplantation (HSCT) have improved long-term survival, but they have also led to late complications, such as nephropathy. However, the safety and feasibility of kidney transplantation (KT) in patients with HSCT-related end-stage kidney disease (ESKD) remain unclear.
AIM: This study aimed to evaluate the feasibility and clinical outcomes of KT in patients with ESKD following HSCT.
METHODS: This study retrospectively analysed eight patients with ESKD who underwent KT following HSCT for haematologic disorders, including aplastic anaemia (n = 5), acute myeloid leukaemia (n = 2) and chronic myeloid leukaemia (n = 1).
RESULTS: The median time to progression to ESKD was 104 months after HSCT, with a median interval of 138 months between HSCT and KT. The causes of ESKD included diabetic nephropathy (n = 1), hypertensive nephropathy (n = 1), focal segmental glomerulosclerosis (n = 1), thrombotic microangiopathy (n = 1) and unknown aetiology (n = 4), with three diagnoses confirmed through kidney biopsy. Three patients received both HSCT and KT from the same donor, allowing them to completely discontinue immunosuppressive therapy. During a median follow-up of 55 months (range 2-143 months), there was only one case of acute T-cell-mediated rejection, and one patient died from sepsis due to a urinary tract infection. Notably, none of the patients experienced a recurrence of their original haematologic disease.
CONCLUSION: Despite concerns regarding immunosuppression and the risk of infection in this high-risk population, both patient and graft outcomes were favourable. These findings suggest that KT is a feasible and effective treatment option for patients with ESKD following HSCT, particularly when managed with personalised strategies.
AIM: This study aimed to evaluate the feasibility and clinical outcomes of KT in patients with ESKD following HSCT.
METHODS: This study retrospectively analysed eight patients with ESKD who underwent KT following HSCT for haematologic disorders, including aplastic anaemia (n = 5), acute myeloid leukaemia (n = 2) and chronic myeloid leukaemia (n = 1).
RESULTS: The median time to progression to ESKD was 104 months after HSCT, with a median interval of 138 months between HSCT and KT. The causes of ESKD included diabetic nephropathy (n = 1), hypertensive nephropathy (n = 1), focal segmental glomerulosclerosis (n = 1), thrombotic microangiopathy (n = 1) and unknown aetiology (n = 4), with three diagnoses confirmed through kidney biopsy. Three patients received both HSCT and KT from the same donor, allowing them to completely discontinue immunosuppressive therapy. During a median follow-up of 55 months (range 2-143 months), there was only one case of acute T-cell-mediated rejection, and one patient died from sepsis due to a urinary tract infection. Notably, none of the patients experienced a recurrence of their original haematologic disease.
CONCLUSION: Despite concerns regarding immunosuppression and the risk of infection in this high-risk population, both patient and graft outcomes were favourable. These findings suggest that KT is a feasible and effective treatment option for patients with ESKD following HSCT, particularly when managed with personalised strategies.